These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35535066)

  • 1. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.
    Padole P; Arora A; Sharma P; Chand P; Verma N; Kumar A
    J Clin Exp Hepatol; 2022; 12(2):435-439. PubMed ID: 35535066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
    Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
    J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
    Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL.
    Mir BA; Sharma B; Sharma R; Bodh V; Chauhan A; Majeed T; Haq I; Sharma N; Sharma D
    J Clin Exp Hepatol; 2024; 14(5):101398. PubMed ID: 38628977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
    Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
    J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Mitra A
    Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease.
    Liu TT; Qiu H; Liu SY; Chien C; Wang JH; Wong MW; Yi CH; Lin L; Lei WY; Liang SW; Hung JS; Huang JF; Chen CL; Han MAT
    Kaohsiung J Med Sci; 2022 Oct; 38(10):1012-1019. PubMed ID: 35993503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
    EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience.
    Chaudhuri S; Dutta A; Chakraborty SBD
    JGH Open; 2023 Mar; 7(3):215-220. PubMed ID: 36968568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
    Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
    J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.
    Siddiqui MS; Parmar D; Shaikh F; Forsgren M; Patel S; Bui AT; Boyett S; Patel V; Sanyal AJ
    Liver Transpl; 2023 Sep; 29(9):979-986. PubMed ID: 36847136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
    Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
    Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience.
    Roy S
    Case Rep Med; 2020; 2020():4287075. PubMed ID: 32280349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Bandyopadhyay S; Samajdar SS; Das S
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102174. PubMed ID: 37380128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study.
    Lee HW; Wong GL; Kwok R; Choi KC; Chan CK; Shu SS; Leung JK; Chim AM; Luk AO; Ma RC; Chan HL; Chan JC; Kong AP; Wong VW
    Hepatology; 2020 Oct; 72(4):1230-1241. PubMed ID: 31991487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.
    Anand A; Singh AA; Elhence A; Vaishnav M; Biswas S; Gunjan D; Gamanagatti SR; Nayak B; Kumar R; Shalimar
    J Clin Exp Hepatol; 2022; 12(2):362-371. PubMed ID: 35535086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study.
    Sugihara T; Koda M; Matono T; Okamoto K; Murawaki Y; Isomoto H; Tokunaga S
    Yonago Acta Med; 2017 Jun; 60(2):106-112. PubMed ID: 28701893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.